top of page
Writer's pictureMayta

In-depth Analysis of ANCA-Associated Vasculitis P-ANCA (Perinuclear ANCA) and C-ANCA (Cytoplasmic ANCA): Histology, Immunology, Clinical Presentation, and Diagnostic Criteria



Introduction: ANCA-associated vasculitis (AAV) refers to a group of autoimmune diseases characterized by inflammation of small to medium-sized blood vessels, leading to multi-organ damage. This group includes Granulomatosis with Polyangiitis (GPA, formerly Wegener's Granulomatosis), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome). This article provides a detailed exploration of the histological features, immunological mechanisms, clinical presentation, and diagnostic criteria of AAV, emphasizing specific numerical values where applicable.

P-ANCA (Perinuclear ANCA)

  1. Histology:

    • Microscopic Polyangiitis (MPA):

      • Necrotizing Vasculitis: Characterized by necrotizing inflammation of small vessels without granuloma formation.

      • Pauci-Immune Crescentic Glomerulonephritis: Found in approximately 80% of MPA cases, this kidney involvement typically shows crescents in more than 50% of glomeruli on biopsy.

    • Eosinophilic Granulomatosis with Polyangiitis (EGPA):

      • Eosinophilic Infiltration: Eosinophils infiltrate tissues at a level typically exceeding 1,500 eosinophils/μL, which is considered diagnostic.

      • Granulomas: Granulomas are present but often smaller and less organized compared to GPA.

  2. Immunology:

    • P-ANCA: Detected in approximately 70% of MPA patients and 40-60% of EGPA patients. P-ANCA primarily targets Myeloperoxidase (MPO), with anti-MPO antibodies found in more than 80% of P-ANCA positive cases.

  3. Clinical Presentation:

    • Microscopic Polyangiitis (MPA):

      • Renal Involvement: Present in 90% of cases, with manifestations such as hematuria, proteinuria, and rapidly progressive glomerulonephritis (RPGN).

      • Pulmonary Capillaritis: Occurs in 30-50% of patients, often presenting with hemoptysis.

    • Eosinophilic Granulomatosis with Polyangiitis (EGPA):

      • Asthma: A history of asthma is found in over 95% of patients.

      • Eosinophilia: Peripheral blood eosinophilia is typically greater than 10% of total leukocyte count.

  4. Diagnostic Criteria:

    • P-ANCA Testing: The presence of P-ANCA with anti-MPO specificity is a key diagnostic marker. In MPA, the sensitivity is approximately 70-80%, and in EGPA, it ranges from 40-60%.

    • ANCA Titer Levels: A titer greater than 1:160 is considered clinically significant for P-ANCA.

C-ANCA (Cytoplasmic ANCA)

  1. Histology:

    • Granulomatosis with Polyangiitis (GPA):

      • Granulomas: Necrotizing granulomas are found in 80-90% of patients with GPA, particularly in the respiratory tract.

      • Pauci-Immune Crescentic Glomerulonephritis: Present in 60-80% of cases, characterized by crescents in more than 50% of glomeruli on biopsy.

  2. Immunology:

    • C-ANCA: Detected in approximately 90% of patients with active GPA. C-ANCA primarily targets Proteinase 3 (PR3), with anti-PR3 antibodies present in more than 90% of C-ANCA positive cases.

  3. Clinical Presentation:

    • Upper Respiratory Tract Involvement: Occurs in about 90% of GPA patients, with symptoms such as chronic sinusitis, nasal crusting, and epistaxis.

    • Pulmonary Involvement: Found in 60-80% of cases, often presenting with nodules, cavitations, or hemoptysis.

    • Renal Involvement: Seen in approximately 80% of cases, often presenting as rapidly progressive glomerulonephritis (RPGN).

  4. Diagnostic Criteria:

    • C-ANCA Testing: The presence of C-ANCA with anti-PR3 specificity is highly sensitive and specific for GPA, with a sensitivity of approximately 90% and specificity of over 95%.

    • ANCA Titer Levels: A titer greater than 1:160 is considered clinically significant for C-ANCA.

Diagnostic Approach and Management:

  1. Initial Diagnostic Workup:

    • ANCA Testing: Both C-ANCA and P-ANCA titers should be evaluated. Specificity for anti-PR3 and anti-MPO should be confirmed using ELISA.

    • Renal Biopsy: Indicated in cases with suspected glomerulonephritis to confirm pauci-immune crescentic glomerulonephritis.

    • Imaging: Chest CT scans should be performed to assess for pulmonary nodules, cavitations, or diffuse alveolar hemorrhage, particularly in patients with respiratory symptoms.

  2. Induction Therapy:

    • High-Dose Glucocorticoids: Initiated at 1 mg/kg/day, typically up to 60-80 mg/day of prednisone, with a gradual taper.

    • Cyclophosphamide: Administered at 2 mg/kg/day orally or intravenously in severe cases, particularly with renal involvement.

    • Rituximab: An alternative to cyclophosphamide, given as 375 mg/m² weekly for 4 weeks.

  3. Maintenance Therapy:

    • Azathioprine: Administered at 1-2 mg/kg/day orally to maintain remission.

    • Methotrexate: An alternative at 15-25 mg weekly, particularly in patients with less severe disease.

    • Long-term Monitoring: Regular follow-up every 3-6 months, with ANCA titers, renal function tests, and chest imaging as indicated.

  4. Supportive Care:

    • Hypertension Management: ACE inhibitors or ARBs are recommended, particularly in patients with renal involvement.

    • Infection Prophylaxis: Trimethoprim-sulfamethoxazole is often used to prevent Pneumocystis jirovecii pneumonia in patients on long-term immunosuppressants.

Conclusion:

ANCA-associated vasculitis represents a challenging group of diseases requiring precise diagnostic and therapeutic strategies. Understanding the histological features, immunological markers, and clinical presentations is essential for early diagnosis and effective management. With a focus on specific numerical values and criteria, clinicians can better navigate the complexities of AAV and provide targeted care to improve patient outcomes.

Recent Posts

See All

Ischemic stroke keeps BP?

For ischemic stroke, AHA/ASA guidelines recommend keeping BP < 185/110 mmHg with IV t-PA, and allowing BP < 220/120 mmHg without t-PA....

ระบบบริการปฐมภูมิ (Primary Health Care) ในประเทศไทย

ระบบบริการปฐมภูมิถือเป็นรากฐานสำคัญของระบบสาธารณสุขในประเทศไทย มีบทบาทในการดูแลสุขภาพขั้นต้นให้แก่ประชาชน โดยเฉพาะในพื้นที่ชนบทและชุมชนห่...

คุณลักษณะและการจัดระบบบริการปฐมภูมิในประเทศไทย

การบริการปฐมภูมิ (Primary Health Care) มีบทบาทสำคัญในระบบสาธารณสุข เนื่องจากเป็นจุดแรกที่ประชาชนสามารถเข้าถึงการดูแลสุขภาพได้อย่างเหมาะสม...

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
Post: Blog2_Post
bottom of page